- Home
- LFST vs FOLD Comparison
LFST vs FOLD Comparison
Compare LFST & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- FOLD
- Stock Information
- Founded
- LFST 2015
- FOLD 2002
- Country
- LFST United States
- FOLD United States
- Employees
- LFST N/A
- FOLD N/A
- Industry
- LFST Medical/Nursing Services
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- LFST Health Care
- FOLD Health Care
- Exchange
- LFST Nasdaq
- FOLD Nasdaq
- Market Cap
- LFST 2.1B
- FOLD 2.5B
- IPO Year
- LFST 2021
- FOLD 2007
- Fundamental
- Price
- LFST $4.90
- FOLD $9.03
- Analyst Decision
- LFST Strong Buy
- FOLD Strong Buy
- Analyst Count
- LFST 5
- FOLD 8
- Target Price
- LFST $8.60
- FOLD $27.88
- AVG Volume (30 Days)
- LFST 1.3M
- FOLD 4.4M
- Earning Date
- LFST 11-06-2025
- FOLD 11-04-2025
- Dividend Yield
- LFST N/A
- FOLD N/A
- EPS Growth
- LFST N/A
- FOLD N/A
- EPS
- LFST N/A
- FOLD N/A
- Revenue
- LFST $1,316,483,000.00
- FOLD $571,160,000.00
- Revenue This Year
- LFST $15.35
- FOLD $21.12
- Revenue Next Year
- LFST $14.14
- FOLD $21.23
- P/E Ratio
- LFST N/A
- FOLD N/A
- Revenue Growth
- LFST 13.86
- FOLD 25.35
- 52 Week Low
- LFST $3.74
- FOLD $5.51
- 52 Week High
- LFST $8.61
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- LFST 37.96
- FOLD 66.73
- Support Level
- LFST $5.05
- FOLD $8.72
- Resistance Level
- LFST $5.19
- FOLD $9.29
- Average True Range (ATR)
- LFST 0.15
- FOLD 0.34
- MACD
- LFST -0.03
- FOLD 0.05
- Stochastic Oscillator
- LFST 13.04
- FOLD 81.98
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.